Dr Kathleen Rickard, MD, Chief Medical Officer of Verona Pharma, highlights the debilitating impacts of Chronic Obstructive Pulmonary Disease (COPD) and the need for novel therapeutic approaches to help relieve the burden on patients and caregivers.
COPD is the third leading cause of death worldwide, affecting more than 384 million patients. The condition causes progressive loss of lung function leading to debilitating breathlessness, hospitalisations, and death. Patients struggle to perform basic daily activities such as getting up, eating, and walking, and often have difficulty sleeping. In addition, it prevents people from socialising and enjoying hobbies, often resulting in frustration, anxiety, and depression.